4.11k followers • 19 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 44 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Exact Sciences Corp., the Madison manufacturer of the Cologuard take-home colon cancer test, met its projected 2018 full-year revenue number, reporting total revenue of $454.5 million in an earnings statement Thursday.
Genomic Health stock toppled Thursday after the company offered a big beat on fourth-quarter sales, but earnings were mixed. An analyst says investors are nitpicking gross margins.
US high-grade companies including Fiserv and Keurig Dr Pepper have increasingly turned to term loans, which are cheaper to issue and easier to prepay than longer-term bonds, as they prioritize debt reduction to avert credit rating downgrades. Heavy long-term debt loads incurred in large mergers and acquisitions (M&A), and in some cases slower than expected repayment of that acquisition debt, has spurred a wave of downgrades to the lowest investment grade rungs or even to junk status. Looking to prevent that, new borrowers are refinancing existing term loans with smaller new loans, while others are quickly applying excess cash flow to deleveraging, looking to show they can cut back on the debt loads incurred in costly M&A.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We've lost count of how many times insiders have accumulatedRead More...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in MacroGenics, Inc. (NASDAQ:MGNX) have powerRead More...
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
Soft demand pattern in voice and video businesses, along with decline in switched access are likely to take a toll on Frontier Communications' (FTR) fourth-quarter revenues.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
Synopsys signaled a breakout after topping views, one of four top stocks moving on earnings. Nike fell after a top college basketball player injured himself as his Nike shoe disintegrated.
The following are the top stories in the Wall Street Journal. - Johnson & Johnson said on Wednesday it received subpoenas from the U.S. Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its signature baby powder and other talc-containing products.
Activist investor Starboard Value LP is unhappy with Bristol-Myers Squibb Co.’s deal to buy rival Celgene Corp., and it has moved to install its own set of directors at Bristol-Myers. The hedge fund has nominated five potential directors, including its chief executive, Jeffrey Smith, and has been meeting with the drugmaker’s executives, Bristol-Myers said in a filing Wednesday. The activist proposal comes as Bristol-Myers has a deal in place to buy Celgene that was valued at $74 billion when it was announced earlier this year.
Genomic Health (GHDX) delivered earnings and revenue surprises of 6.67% and 2.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had profit of 23 cents. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results topped Wall Street expectations. ...
Reuters reported last week that Starboard was working with a proxy solicitor to gauge the level of support among Bristol-Myers shareholders for the Celgene deal. If it finds enough discontent, Starboard could agitate against it. Bristol-Myers said Starboard informed the company it had bought roughly one million of its common shares.
Bristol-Myers Squibb confirms Starboard's stake in the company and says the $74 billion deal to acquire cancer drugmaker Celgene is "on track" to close during the third quarter.